PAIM
LFCR icon

Punch & Associates Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Punch & Associates Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-776,460
Closed -$5.03M – 237
2022
Q4 		$5.03M Buy
776,460
+53,260
+7% +$439K 0.33% 117
2022
Q3 		$6.43M Buy
723,200
+332,165
+85% +$3.38M 0.45% 93
2022
Q2 		$3.9M Sell
391,035
-23,926
-6% -$237K 0.27% 131
2022
Q1 		$4.8M Buy
414,961
+315,519
+317% +$3.51M 0.27% 131
2021
Q4 		$1.1M Buy
+99,442
New +$965K 0.06% 176

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Punch & Associates Investment Management's LFCR Position: Q1 2023 in Review

Punch & Associates Investment Management sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 776,460 shares — an estimated $5.03M sold.

Punch & Associates Investment Management first reported a position in LFCR in Q4 2021 and held it in 5 quarters. The position peaked at $6.43M in Q3 2022. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

  • Punch & Associates Investment Management reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
  • Punch & Associates Investment Management sold 776,460 Lifecore Biomedical shares in Q1 2023, an estimated $5.03M.
  • Punch & Associates Investment Management first reported a position in Lifecore Biomedical in Q4 2021 and held it in 5 quarters.
  • Punch & Associates Investment Management's Lifecore Biomedical position peaked at $6.43M in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Punch & Associates Investment Management's 13F filing for Q1 2023, filed 15 May 2023.